Olink Proteomics announces the availability of the most comprehensive, high-multiplex protein biomarker panel for mouse studies

Press releases   •   Dec 14, 2017 07:30 EST

Olink Proteomics today announced the launch of Olink® MOUSE EXPLORATORY, offering 92 high-quality assays to measure mouse proteins. The panel is based on the same, well-established Proximity Extension Assay (PEA) technology behind Olink’s portfolio of high-multiplex panels for human protein biomarker discovery, and has been developed to the same high standards of validation and quality control.

Olink Proteomics AB announce strategic acquisition of Agrisera AB to accelerate production of dedicated antibodies for development of new immunoassays

Press releases   •   May 12, 2020 07:59 EDT

Olink today announced the acquisition of Agrisera, a Swedish company specializing in polyclonal and monoclonal antibody production. The acquisition is an important milestone for Olink in its aim to rapidly increase the number of assays available for its unique PEA technology which allows for an unparalleled multiplexing with rigorous validation for each assay.

Olink Proteomics announces a new oncology-focused biomarker panel that expands its protein library to over 1100 high-quality assays

Press releases   •   Dec 13, 2018 07:30 EST

Olink Proteomics today announced the launch of Olink® ONCOLOGY III, a new oncology-focused biomarker panel that complements and expands on Olink's growing portfolio of thoroughly validated assays, extending the power of the Olink platform for discovery-scale applications to 1164 different human protein biomarkers.

Protein biomarkers making an impact in clinical trials for Atopic Dermatitis.

News   •   Oct 31, 2018 08:58 EDT

DS Biopharma have announced in a press release that oral treatment with the immunomodulating, bioactive lipid, DS107 reversed the molecular signature of Atopic Dermatitis (AD) patients in a phase 2b clinical trial. Protein data generated using Olink’s biomarker panels provided evidence of the favorable effect of the compound, based on the reversal of the AD molecular signature. For more details, please read the full press release. If you have any questions about this exciting development, please contact DS Biopharma directly.

DS Biopharma have announced in a press release that oral treatment with the immunomodulating, bioactive lipid, DS107 reversed the molecular signature of Atopic Dermatitis (AD) patients in a phase 2b clinical trial.

Read more »

Olink Proteomics announces a new biomarker panel that expands its protein library to over 1000 high-quality assays

Press releases   •   Aug 31, 2018 08:00 EDT

Olink Proteomics today announced the launch of Olink® NEURO EXPLORATORY, a new biomarker panel that complements and expands on Olink's growing portfolio of high quality protein assays, extending the power of the Olink platform for discovery-scale application to 1072 different protein biomarkers. This will enable scientists to cast an even broader net in their protein biomarker screening studies.

New booklet from Science & Olink

News   •   Oct 18, 2017 06:49 EDT

Olink present a new sponsored Supplement produced by the Science/AAAS Custom Publishing Office that will enable the scientific community to learn more about biomarker discovery strategies to advance precision medicine.

Olink Proteomics announces the availability of three additional biomarker panels focused on key biological processes with broad clinical relevance

Press releases   •   Feb 16, 2017 08:00 EST

Olink Proteomics today announced the launch of three new precision proteomics panels, further expanding its rapidly growing library of high quality human protein biomarker assays to almost 1000. The focus areas for these three new panels are Cardiometabolic, Cell Regulation and Development.

Olink Proteomics announces the availability of three new biomarker panels to further explore the complexities of the human proteome

Press releases   •   Nov 29, 2016 08:32 EST

Olink Proteomics today announced the launch of three new precision proteomics panels, significantly expanding its library of high quality human protein biomarker assays, from 460 to over 700. This series of new panels is designed to enable scientists to extend their discovery capabilities for studying the plasma proteome by casting a broader net.

Olink Proteomics announces the availability of the broadest and most complete protein biomarker panel for immuno-oncology

Press releases   •   Sep 21, 2016 10:43 EDT

Olink Proteomics today announced that Proseek® Multiplex Immuno-Onc I, the broadest protein biomarker panel targeting critical biological process related to immunotherapy, is now available for immediate delivery. Developed to meet a clearly expressed need from customers, the panel is designed to help companies, scientists and clinicians working with immunotherapy-based approaches to treat cancer.

Open for business in the USA: Olink Proteomics unveils a new office and analysis service laboratory in the Boston area.

Press releases   •   May 31, 2016 06:29 EDT

Olink Proteomics is delighted to announce the opening of new office and laboratory facilities in Watertown, Massachusetts. This heralds the establishment of the company’s first major regional organization outside of Sweden, and will support the rapidly growing business in the United States.

Images & Videos 1 image, 2 videos

Contacts 2 contacts

  • Press Contact
  • Marketing Communications Manager
  • Marketing Communications
  • gavfryit.fgbradjnkkflipln@cpolhninkhk.emcoahmvk
  • +46722518330
  • +46722518330

About Olink Proteomics

Swedish company Olink Proteomics provides innovative solutions for targeted human protein biomarker discovery.

Address

  • Olink Proteomics
  • 201 Dexter Avenue
  • 02472 Watertown, MA
  • United States
  • Our homepage